Repositioning an old antihelminthic agent of niclosamide in human
disease and cancer
- Guiling Wang
, - Jinxiu Du,
- Zhan Wang,
- Junyi Ren,
- Huan Wang,
- Jia Liu
Abstract
Niclosamide is a FDA-approved anthelminthic drug for the treatment of
parasitic infection. However, over the past few years, the increasing
evidence has shown that Niclosamide could treat diseases beyond
parasitic diseases, which include metabolic diseases, immune system
diseases, bacterial and viral infections, other types of diseases and
cancer. Therefore, we systematically review the pharmaceutical
activities and therapeutic prospects of Niclosamide in human disease and
cancer, and summarize the related molecular mechanisms and signaling
pathways, which provides theoretical support for the new therapeutic
value of old drug.